HPV VACs

Vaccinate Adolescents against Cancers

American Cancer Society
Partner Newsletter

April 2016

Please find **key resources** below that are available for your use and the **latest news** and studies on HPV vaccination. Reach out to your American Cancer Society contact for more information and additional support.

HPV Vaccination IN THE NEWS

Anal cytology and human papillomavirus genotyping in women with a history of genital tract neoplasia compared with low-risk women. Obstetrics and Gynecology.

HPV vaccine acceptance among adolescent males and their parents in two suburban pediatric practices. Vaccine.

Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009-2013. Emerging Infectious Diseases.

"I think they're all basically the same": Parents' perceptions of human papilloma virus (HPV) vaccine compared with other adolescent vaccines. Child Care Health and Development.

National and state-level impact and costeffectiveness of nonavalent HPV vaccination in the United States. Proceedings of the National Academy of Science of the United States of America.

Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012. Vaccine.

Just the FACTS!

Read and share the full Just the Facts document!

FACT: The vaccine is effective and prevents cancer



In the studies that led to the approval of HPV vaccines, the vaccines provided nearly 100% protection against persistent cervical infections with HPV types 16 and 18, plus the pre-cancers that those persistent infections can cause. In addition, a clinical trial of HPV vaccines in men indicated that they can prevent anal cell changes caused by persistent infection and genital warts.

TALKING POINT: The vaccine has been proven, through numerous studies, to prevent the cell changes and infections that correspond with multiple HPV-associated cancers.

Reference:

National Cancer Institute. (2015). Human Papillomavirus (HPV) Vaccines. Retrieved from http://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-vaccine-fact-sheet#r18

Resource SPOTLIGHT




Discontinuing HPV2 and HPV4

Beginning April 1, HPV2 (Cervarix) and HPV4 (Gardasil) are no longer available for purchase from the CDC/Vaccines for Children program. The CDC expects to have stock of HPV2 and HPV4 until the end of April and will fulfill prior orders as available. This change is reflected in the CDC Vaccine Price List, which lists the vaccines available for purchase. Gardasil 9 will now be the sole HPV vaccine available through government programs. There is not yet any information as to if, or when, HPV2 and HPV4 will be discontinued for private purchase.

HIBMENCY [3]	MENHIBRIX®	58160- 0801-11	10 pack - 1 dose vial	\$10.53	\$24.71	03/31/2017	GlaxoSmithKline	200-2016 89085
HPV – Human Papillomavirus 9-valent [5]	Gardasil@9	00006- 4119-03	10 pack - 1 dose vial	\$141.60	\$177.70	03/31/2017	Merck	200-201¢ 89086
MENB – Meningococcal Group B [5]	Trumenba®	00005- 0100-10	10 pack - 1 dose syringe	\$95.75	\$115.75	03/31/2017	Pfizer	200-201¢ 89087

National Foundation for Infectious Diseases



The NFID has released their final version of <u>Call to Action:</u> Addressing New and Ongoing Adolescent Vaccination Challenges.

A result of the February 2016 NFID Roundtable, this resource provides key information on the importance of adolescent vaccinations, including HPV.

American Society of Clinical Oncology

On April 11, ASCO published a policy statement which urges increased use of HPV vaccination to prevent cancer. In their press release they state: *Use of human papillomavirus (HPV) vaccines should be rapidly expanded to protect thousands of young people in the United States—and millions worldwide—from life-threatening cancers.*



Find ASCO's HPV-related resources below:

- Complete ACSO Statement: <u>Human Papillomavirus Vaccination for Cancer Prevention</u>
- ASCO press release: <u>ASCO Urges Aggressive Efforts to Increase HPV Vaccination and Prevent</u> Cancer
- Related infographic: <u>If You Could Prevent Cancer, Would You?</u>



Resource SPOTLIGHT

New HPV Brief: CHOP's Policy Lab and Vaccine Education Center



Dr. Kristen Feemster and colleagues at the Children's Hospital of Philadelphia (CHOP) released a new Evidence to Action brief: Increasing HPV Vaccination Rates Among Adolescents: Challenges and Opportunities. The brief addresses barriers to HPV vaccination and provides recommendations to increase vaccination rates.

Upcoming #PreteenVaxScene Webinar

Join in Thursday, May 19 at 1 PM ET for a new webinar in the Adolescent Immunization Series, "Research Project Update: AFIX Strategies for Improving HPV Vaccination Rates in the Field." Presented by Dr. Melissa Gilkey and Chrystal Averette, the webinar will discuss strategies and tools used in an ongoing study to adapt AFIX to the challenges associated with HPV vaccination.



Updated CDC and IAC Resources

The CDC and IAC have released new and updated immunization resources, including immunization report cards and a Spanish version of the Immunization Schedule for Preteens and Teens.

- Spanish version of Immunization Schedule for Preteens and Teens
- Teen Immunization Report Cards

Last name	First	name	M.I.	Birt	hdate	Measles, Mumps Rubella
Vaccine	Type of vaccine	Date given mo/day/yr	Healthcare profe	ssional ne	Date next dose due	(MMR, MMRV) Varicella
H. influenzae type b (Hib, Hib-HepB, DTaP-IPV/Hib, DTaP/Hib.						(chickenpox) (VAR, MMRV) Hepatitis A (HepA, HepA-HepE
Hib-MenCY)						If combination
Polio (IPV, OPV, DTaP-HepB-IPV, DTaP-IPV/Hib, DTaP-IPV)						Meningococca (MenACWY, MenB, MPSV4, Hib-MenC
Pneumococcal (PCV7, PCV13, PPSV23)						Human papillomavirus (HPV2, HPV4, HPV9)
Rotavirus (RV5 [RotaTeq], RV1 [Rotarix], RV [unknown])						Get v


Vaccine		Type of vaccine	Date given mo/day/yr	Healthcare professional or clinic name	Date next dose due		
Measles, Mum Rubella (MMR, MMRV)	ps,						
Varicella (chickenpox) (VAR, MMRV)	\perp						
Hepatitis A (HepA, HepA-Hep	pB)						
If combination							
Meningococo (MenACWY, Men MPSV4, Hib-Men	В,						
Human papillomaviru (HPV2, HPV4, HPV9)	és.						
C	7						
Get vaccinated against influenza each year to protect yourself and others around you.							

Resource SPOTLIGHT



HPV Cancer Research News

New research published in *JAMA Oncology* provides more evidence of the connection between HPV and head and neck cancers, including squamous cell carcinoma (HNSCC), which includes cancers of the mouth (oral cavity), throat (oropharynx), and lower throat (larynx). For more details on the findings, please visit cancer.org.



IAC Ask the Experts: HPV



IAC's recently updated <u>Ask the Experts</u> section on HPV highlights a variety of questions under the following themes:

- Disease issues
- Vaccine recommendations
- Scheduling and administering vaccines
- Contraindications and precautions
- Vaccine safety

Dr. Melinda Wharton on HPV Vaccination



Dr. Melinda Wharton recently presented on HPV vaccination to the Louisiana Breast and Cervical Health Program. The webinar, <u>HPV Vaccine: Why We Must and How We Can Do Better</u>, is now available for viewing. In addition, PowerPoint slides can be found here.

New CE Opportunity: You are the Key to Cancer Prevention

The CDC has released a <u>new web-on-demand video</u> providing up-to-date information on HPV, HPV vaccination and successful ways to communicate with parents and patients. For more information on CE credits and course expirations, please review <u>this</u> flyer.





cancer.org | 1.800.227.2345 1.866.228.4327 TTY